Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent (NCT00166361) | Clinical Trial Compass
CompletedNot Applicable
Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent
United States29 participantsStarted 2004-02
Plain-language summary
The purpose of this study is to evaluate the safety and efficacy of the Memokath 051 ureteral stent as a long-term temporary and minimally invasive means of providing ureteral drainage in the setting of malignant extrinsic ureteral obstruction secondary to inoperable abdominal or pelvic malignancies. Up to 15 adults who have extrinsic ureteral obstruction secondary to an inoperable abdominal or pelvic malignancy and need ureteral stent drainage will undergo outpatient placement of the ureteral stent. Ongoing monitoring will continue for as long as the stent is in place.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Presence of extrinsic ureteral obstruction
✓. secondary to inoperable pelvic or abdominal malignancy or
✓. secondary to changes caused by surgery, chemotherapy, or radiation for pelvic and/or abdominal malignancies who have had \>2 standard double J stent exchanges with no prospect of being stent-free
✓. Life expectancy greater than 4 months
✓. Adult patient (18 years of age or older)
✓. Preoperative medical examination clearing the patient for general anesthesia
✓. No active urinary tract infection by urinalysis and urine culture.
Exclusion criteria
✕. Ureteral obstruction of a benign or intrinsic etiology